FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

[cafead]

via Amid high-profile reports of "rebound" cases in people who received Pfizer's COVID-19 oral antiviral, Paxlovid, FDA commissioner Robert Califf is standing behind the agency's rationale in granting its authorization.

article source